# Janssen Pharmaceutica

> company

**Wikidata**: [Q903523](https://www.wikidata.org/wiki/Q903523)  
**Wikipedia**: [English](https://en.wikipedia.org/wiki/Janssen_Pharmaceuticals)  
**Source**: https://4ort.xyz/entity/janssen-pharmaceutica

## Summary
Janssen Pharmaceutica is a pharmaceutical company headquartered in Beerse, Belgium, and owned by the U.S. multinational Johnson & Johnson. Founded by the Belgian scientist Paul Janssen, the company operates as a business enterprise within the pharmaceutical industry and is recognized for developing the Ad26.COV2.S COVID-19 vaccine.

## Key Facts
- **Founded By:** Paul Janssen (Belgian scientist, 1926–2003).
- **Parent Organization:** Johnson & Johnson.
- **Headquarters:** Beerse, Antwerp, Belgium.
- **Industry:** Pharmaceutical industry.
- **Inception Dates:** October 23, 1934, and January 1, 1953.
- **Employees:** 10,001 or more.
- **Notable Product:** Ad26.COV2.S (COVID-19 vaccine).
- **Website:** https://innovativemedicine.jnj.com/
- **Social Media:** Twitter (@janssenus, @JanssenEMEA, @JanssenFRA), Instagram (@janssenglobal), YouTube (UCt0eSwvMgJuTYSSjIZCdJSw), LinkedIn (jnjinnovmedbelgium).
- **Classification:** Business, Enterprise, Company, Juridical Person.
- **Country of Operation:** Belgium.
- **Wikidata IDs:** Q4830453, Q6881511.

## FAQs
**Who founded Janssen Pharmaceutica?**
The company was founded by Paul Janssen, a Belgian scientist who lived from 1926 to 2003.

**Where is Janssen Pharmaceutica located?**
The company is headquartered in Beerse, a municipality located in the province of Antwerp, Belgium.

**What is the relationship between Janssen Pharmaceutica and Johnson & Johnson?**
Janssen Pharmaceutica is owned and operated by Johnson & Johnson, which serves as its parent organization.

**What significant medical product did Janssen develop?**
Janssen Pharmaceutica developed Ad26.COV2.S, a COVID-19 vaccine produced under the Johnson & Johnson banner.

**What industry does Janssen Pharmaceutica operate in?**
It operates within the pharmaceutical industry, engaging in the development, production, and marketing of drugs and medications.

## Why It Matters
Janssen Pharmaceutica serves as a critical component of the global healthcare infrastructure, specifically as the pharmaceutical arm of Johnson & Johnson in Europe. Its development of the Ad26.COV2.S vaccine played a pivotal role in the global response to the COVID-19 pandemic, contributing to public health efforts worldwide. As a major employer with over 10,000 employees, the company acts as a significant economic engine in the Beerse region and reinforces Belgium's status as a hub for scientific innovation and pharmaceutical research. The organization embodies the characteristics of a modern business enterprise, functioning as a juridical person dedicated to commercial and industrial activity aimed at generating economic profit through medical advancement.

## Notable For
- **COVID-19 Vaccine Development:** Creation of the Ad26.COV2.S vaccine.
- **Founder Legacy:** Established by Paul Janssen, a prominent figure in pharmaceutical science.
- **Operational Scale:** Employs a workforce exceeding 10,000 individuals.
- **Global Identifiers:** Possesses extensive indexing in global knowledge systems, including ISNI, VIAF, and Library of Congress IDs.
- **Digital Presence:** Maintains a diverse and active social media footprint across multiple regions (US, EMEA, France).

## Body

### Corporate Identity and Classification
Janssen Pharmaceutica is defined as a company and an enterprise, operating as an organization undertaking commercial, industrial, and professional activities. As a business, it is classified as a juridical person and an economic entity with the primary goal of generating profit. The company is a subsidiary of Johnson & Johnson, a U.S. multinational corporation that manufactures medical devices, pharmaceuticals, and consumer packaged goods. Within the hierarchy of corporate entities, Janssen Pharmaceutica is identified by the Wikidata IDs Q4830453 and Q6881511.

### Geographic Location and Context
The company's headquarters are situated in Beerse, a municipality in the province of Antwerp, Belgium. Belgium, the country of operation, is a sovereign state and constitutional republic located in Western Europe, known for its high population density and political stability. The region is characterized by a federal parliamentary monarchy with Brussels as its capital. Belgium boasts a robust economy with a nominal GDP of $644.78 billion (2023) and is a founding member of the European Union and NATO. The specific location of Janssen's formation and headquarters is identified by the Wikidata ID Q723728.

### History and Founding
Janssen Pharmaceutica was founded by Paul Janssen, a Belgian scientist recognized for his contributions to the field. The entity has two recorded inception dates: October 23, 1934, and January 1, 1953. Paul Janssen, who lived from 1926 to 2003, established the organization which has since grown into a major pharmaceutical enterprise.

### Products and Innovation
The company is actively involved in the pharmaceutical industry, which develops, produces, and markets drugs licensed for use as medications. A notable product developed by Janssen Pharmaceutica is Ad26.COV2.S, a COVID-19 vaccine associated with Johnson & Johnson. This innovation highlights the company's role in addressing global health challenges through scientific research and development.

### Operations and Scale
Janssen Pharmaceutica is a large-scale enterprise, employing over 10,001 people. Its operations are integrated into the broader structure of Johnson & Johnson, leveraging the resources and reach of its parent organization to maximize its impact in the pharmaceutical market. The company functions as an organizational unit producing goods and services, benefiting from autonomy in decision-making regarding resource allocation.

### Digital Presence and Identifiers
The company maintains a significant digital footprint to facilitate communication and brand management.
*   **Website:** https://innovativemedicine.jnj.com/
*   **Social Media:**
    *   Twitter: @janssenus, @JanssenEMEA, @JanssenFRA
    *   Instagram: @janssenglobal
    *   YouTube: UCt0eSwvMgJuTYSSjIZCdJSw
    *   LinkedIn: jnjinnovmedbelgium

Janssen Pharmaceutica is cataloged in numerous global library and knowledge systems, ensuring persistent identification across various platforms:
*   **ISNI:** 0000000406230341
*   **VIAF:** 125497068
*   **Library of Congress (LCCN):** n81042316
*   **BNF:** 12488145z
*   **IdRef (SUDOC):** 03408990X
*   **GND:** ko2002149167
*   **LEI:** 549300OLOH8YMZM9O838
*   **Crossref Funder ID:** 50148
*   **ROR ID:** 04yzcpd71
*   **Instagram ID:** dndubmym
*   **YouTube Channel ID:** UCt0eSwvMgJuTYSSjIZCdJSw
*   **Grid ID:** grid.419619.2
*   **ORCID:** 04yzcpd71
*   **Wikidata:** Q4830453, Q6881511

## References

1. GRID Release 2017-01-10
2. Virtual International Authority File
3. BnF authorities
4. Freebase Data Dumps. 2013
5. [Source](https://www.linkedin.com/company/janssen-pharmaceutical-companies-of-johnson-and-johnson/about/)
6. Google Knowledge Graph
7. GRID Release 2016-05-31
8. Quora
9. Aligned ISNI and Ringgold identifiers for institutions
10. [Source](https://amadeus.bvdinfo.com/version-2019829/)
11. [Source](https://golden.com/wiki/Janssen_Pharmaceuticals-VXX46V)
12. National Library of Israel Names and Subjects Authority File
13. YouTube API